System Vaccinology: From Rationale Design to High-Throughput Vaccine Development

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 4644

Special Issue Editor


E-Mail Website
Guest Editor
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital, IMIBIC Building, Av. Menéndez Pidal, s/n, 14004 Córdoba, Spain
Interests: vaccine development; immunology; immunotoxicology; vaccine adjuvants

Special Issue Information

Dear Colleagues,

Vaccine development has evolved from empirical trial-and-error strategies to rational design with the use of big data that reduce time and costs to obtain more effective and safer vaccines. The use of computational tools combined with in vitro methods of screening helps to identify vaccine candidates for further experimentation and anticipate the best immunogens that are likely to induce protective responses. To evaluate the vaccine responses in the discovery phase, systems vaccinology methods can be used to study the mechanism of action of vaccine formulations, in vitro as well as in both experimental animals and clinical studies.

Given the importance and topicality of systems vaccinology and big data in the vaccine development chain, this Special Issue aims to compile a group of works that show the application of bioinformatics and omics techniques at different levels, such as genes, proteins, cells, tissues, and organs, including their interaction with each other, at any stage of vaccine development. All research articles, methodologies, brief communications, reviews, and meta-analyses will be considered to address scientific questions related to these aspects.

We look forward to receiving your contributions.

Dr. Alexander Batista Duharte
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine development
  • adjuvants
  • antigen prediction
  • systems vaccinology
  • rationale design
  • network analysis
  • proteomics
  • transcriptomics
  • metabolomics
  • big data

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 6981 KiB  
Article
Multi-Epitope Vaccine Design against Monkeypox Virus via Reverse Vaccinology Method Exploiting Immunoinformatic and Bioinformatic Approaches
by Kunal Bhattacharya, Israa M. Shamkh, Mohammad Shahbaz Khan, Marwa M. Lotfy, Jean Bosco Nzeyimana, Reem Fawaz Abutayeh, Nadia M. Hamdy, Dalia Hamza, Nongmaithem Randhoni Chanu, Pukar Khanal, Atanu Bhattacharjee and Emad B. Basalious
Vaccines 2022, 10(12), 2010; https://doi.org/10.3390/vaccines10122010 - 25 Nov 2022
Cited by 20 | Viewed by 3966
Abstract
(1) Background: The monkeypox virus is a zoonotic orthopox DNA virus that is closely linked to the virus. In light of the growing concern about this virus, the current research set out to use bioinformatics and immunoinformatics to develop a potential vaccine against [...] Read more.
(1) Background: The monkeypox virus is a zoonotic orthopox DNA virus that is closely linked to the virus. In light of the growing concern about this virus, the current research set out to use bioinformatics and immunoinformatics to develop a potential vaccine against the virus. (2) Methods: A multiepitope vaccine was constructed from the B-cell and T-cell epitopes of the MPXVgp181 strain using adjuvant and different linkers. The constructed vaccine was predicted for antigenicity, allergenicity, toxicity, and population coverage. In silico immune simulation studies were also carried out. Expression analysis and cloning of the constructed vaccine was carried out in the pET-28a(+) vector using snapgene. (3) Results: The constructed vaccine was predicted to be antigenic, non-allergenic, and non-toxic. It was predicted to have excellent global population coverage and produced satisfactory immune response. The in silico expression and cloning studies were successful in E. coli, which makes the vaccine construct suitable for mass production in the pharmaceutical industry. (4) Conclusion: The constructed vaccine is based on the B-cell and T-cell epitopes obtained from the MPXVgp181 strain. This research can be useful in developing a vaccine to combat the monkeypox virus globally after performing in-depth in vitro and in vivo studies. Full article
Show Figures

Graphical abstract

Back to TopTop